Pharmaceuticals News and Research

RSS

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

5 Dec 2013

Quality Management Certification awarded to Marken Singapore

Marken announced today that their Singapore biological kit-building facility has now been certified to International Standards Organization (ISO) 13485 standards for the storage and distribution of medical devices.

5 Dec 2013

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.

5 Dec 2013

All China Biotech Conference & Exhibition to be held in Nanjing on May, 2014

Jointly organized by Nanjing Pushlong Business Management Co., Ltd. and more than 10 national associations, the All China Biotech Conference & Exhibition (Biotech China) will be held in Nanjing on May 14-16, 2014, providing a platform for business and academic exchanges.

5 Dec 2013

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies.

5 Dec 2013

SingHealth, Duke-NUS Graduate Medical School join global network to boost healthcare research

SingHealth and Duke-NUS Graduate Medical School, which form Singapore's largest academic healthcare cluster, are joining a new global research network to accelerate the discovery of treatments and cures. They will be signing a memorandum of understanding with the Eureka Institute for Translational Medicine today.

5 Dec 2013

B2G2 component of grape seed extract induces apoptosis in prostate cancer cells

A University of Colorado Cancer Center study published online ahead of print in the journal Nutrition and Cancer describes the laboratory synthesis of the most active component of grape seed extract, B2G2, and shows this synthesized compound induces the cell death known as apoptosis in prostate cancer cells while leaving healthy cells unharmed.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

Blocking Cdh1 protein could accelerate development of new therapies targeting cancer

The laboratory of Marcos Malumbres, who is head of the Spanish National Cancer Research Centre's (CNIO) Cell Division & Cancer Group, working alongside Isabel Fari-as' team from the University of Valencia, shows, in a study published today in the journal Nature Communications, how in mice the elimination of the Cdh1 protein -a sub-unit of the APC/C complex, involved in the control of cell division-prevents cellular proliferation of rapidly dividing cells.

5 Dec 2013

Researchers discover how PC7 protein affects certain types of cognitive performance

A team of Montr-al researchers at the IRCM led by Dr. Nabil G. Seidah, in collaboration with Dr. William C. Wetsel's team at Duke University in the United States, discovered that the protein PC7 plays a critical role in the brain by affecting certain types of cognitive performance such as anxiety, learning and emotional memory. Their results, recently published in the scientific journals Proceedings of the National Academy of Sciences (PNAS) and Nature, could have a significant impact on regulating behaviour related to anxiety disorders and trauma.

4 Dec 2013

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company's Gencaro Investigational New Drug application for atrial fibrillation has been accepted by the U.S. Food and Drug Administration and is now active.

4 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Electronic informational technologies provide better means of transparency in health care costs

-The "shroud of secrecy" once draped across private health care service costs could be lifted with innovative information technologies, Princeton University professor Uwe Reinhardt wrote in a review published by the Journal of the American Medical Association (JAMA).

4 Dec 2013

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Ligand Pharmaceuticals Incorporated is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol® material.

4 Dec 2013

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

Frost & Sullivan released today its three big predictions for the global healthcare market. Based on a '2013 Search for Growth' survey which involved 1835 executives in more than 40 countries worldwide, Frost & Sullivan's insight highlights new areas of growth. mHealth, Cloud in Healthcare and Regulatory Environments will be the key subjects in 2014 and beyond.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

New male contraceptive pill could soon be available

A new male contraceptive could be on the horizon after scientists identified a novel way to block the transport of sperm during ejaculation.

4 Dec 2013

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement.

4 Dec 2013

Pyridomycin turns out to be a lethal weapon against TB

Technology has made it possible to synthesize increasingly targeted drugs. But scientists still have much to learn from Mother Nature. Pyridomycin, a substance produced by non-pathogenic soil bacteria, has been found to be a potent antibiotic against a related strain of bacteria that cause tuberculosis.

4 Dec 2013

Pharmaceuticals News and Research

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

Quality Management Certification awarded to Marken Singapore

Researchers find correlation between biomarker and patient’s ability to respond to Imprime PGG

All China Biotech Conference & Exhibition to be held in Nanjing on May, 2014

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

SingHealth, Duke-NUS Graduate Medical School join global network to boost healthcare research

B2G2 component of grape seed extract induces apoptosis in prostate cancer cells

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Blocking Cdh1 protein could accelerate development of new therapies targeting cancer

Researchers discover how PC7 protein affects certain types of cognitive performance

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Electronic informational technologies provide better means of transparency in health care costs

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

New male contraceptive pill could soon be available

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Pyridomycin turns out to be a lethal weapon against TB

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence